David Bautz, PhD, Senior Biotechnology Analyst for Zacks Small-Cap Research, with 6 years of direct experience in the securities and investment industry. His focus at Zacks has been on Oncology, Infectious Diseases, Neurology, Specialty Pharma, Cell Therapy, and Metabolic Disorders. David’s research articles have been posted extensively on Yahoo Finance News and throughout life sciences social media circles.

Prior to joining Zacks in 2014, David was an NRSA postdoctoral fellow investigating the genetics of colorectal cancer morphology. During his tenure as a postdoctoral fellow, David also conducted research developing active immunotherapies and monoclonal antibodies as potential treatments for colorectal cancer. He has published in journals such as Oncoimmunology, G3, The Journal of the American Society of Nephrology and Kidney International.

David obtained his PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill in 2008. His dissertation research focused on the characterization of autoantibodies in patients suffering from an orphan autoimmune disease. Prior to obtaining his PhD, David worked for two years as a research associate at Human Genome Sciences, Inc., a biotechnology company that was eventually acquired by GlaxoSmithKline. David obtained his BS and MS degrees in Biochemistry from Virginia Tech.